Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18672959 | TAURINE SUPPLEMENTED CELL CULTURE MEDIUM AND METHODS OF USE | May 2024 | March 2025 | Allow | 9 | 2 | 0 | No | No |
| 18672979 | TAURINE SUPPLEMENTED CELL CULTURE MEDIUM AND METHODS OF USE | May 2024 | March 2025 | Allow | 9 | 2 | 0 | No | No |
| 18582361 | COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACID | February 2024 | August 2024 | Allow | 6 | 1 | 0 | No | No |
| 18682853 | HIGH-THROUGHPUT PRECISION GENOME EDITING IN HUMAN CELLS | February 2024 | May 2025 | Abandon | 16 | 2 | 0 | No | No |
| 18431504 | POLYNUCLEOTIDE COMPOSITIONS, RELATED FORMULATIONS, AND METHODS OF USE THEREOF | February 2024 | September 2024 | Allow | 8 | 1 | 0 | Yes | No |
| 18510460 | ARTICLES OF MANUFACTURE AND METHODS FOR TREATMENT USING ADOPTIVE CELL THERAPY | November 2023 | January 2025 | Abandon | 14 | 2 | 0 | No | No |
| 18371959 | TAURINE SUPPLEMENTED CELL CULTURE MEDIUM AND METHODS OF USE | September 2023 | July 2024 | Allow | 10 | 2 | 0 | Yes | No |
| 18447651 | COMPOSITIONS AND METHODS COMPRISING ENGINEERED SHORT NUCLEAR RNA (SNRNA) | August 2023 | February 2024 | Allow | 7 | 0 | 0 | No | No |
| 18322961 | ONCOLYTIC VIRUSES FOR MODIFIED MHC EXPRESSION | May 2023 | December 2023 | Allow | 7 | 1 | 0 | No | No |
| 18105374 | Oncolytic Immunotherapy by Tumor Micro-Environment Remodeling | February 2023 | May 2025 | Allow | 27 | 4 | 0 | No | No |
| 18080253 | ONCOLYTIC VIRUSES FOR MODIFIED MHC EXPRESSION | December 2022 | February 2024 | Allow | 14 | 1 | 0 | No | No |
| 18079749 | AAV-Mediated Gene Transfer for Retinopathy | December 2022 | September 2024 | Abandon | 21 | 2 | 0 | Yes | No |
| 18052801 | GENE EDITING SYSTEMS COMPRISING AN RNA GUIDE TARGETING HYDROXYACID OXIDASE 1 (HAO1) AND USES THEREOF | November 2022 | September 2023 | Allow | 11 | 1 | 0 | Yes | No |
| 17964465 | GENETICALLY MODIFIED NON-HUMAN ANIMALS WITH HUMANIZED IMMUNOGLOBULIN LOCUS | October 2022 | June 2023 | Allow | 8 | 1 | 0 | Yes | No |
| 17846868 | ARTICLES OF MANUFACTURE AND METHODS FOR TREATMENT USING ADOPTIVE CELL THERAPY | June 2022 | August 2023 | Allow | 13 | 1 | 0 | Yes | No |
| 17740045 | CODON OPTIMIZED REP1 GENES AND USES THEREOF | May 2022 | August 2022 | Allow | 3 | 1 | 0 | No | No |
| 17646496 | NOVEL PEPTIDE, COMPOSITIONS AND METHOD FOR DELIVERY OF AGENTS INTO CELLS AND TISSUES | December 2021 | March 2023 | Allow | 14 | 2 | 0 | No | No |
| 17616762 | ONCOLYTIC VIRUS FOR TREATING BRAIN TUMORS USING RECOMBINANT NEWCASTLE DISEASE VIRUS INTO WHICH NEWCASTLE DISEASE VIRUS VECTOR-BASED PTEN GENE IS INSERTED AND COMPOSITION FOR TREATING BRAIN TUMORS USING SAME | December 2021 | October 2022 | Allow | 10 | 0 | 0 | No | No |
| 17507996 | Truncated Epiderimal Growth Factor Receptor (EGFRt) for Transduced T Cell Selection | October 2021 | May 2025 | Allow | 43 | 1 | 0 | Yes | No |
| 17502101 | ENHANCED THERAPEUTIC USAGE OF A PURINE NUCLEOSIDE PHOSPHORYLASE OR NUCELOSIDE HYDROLASE PRODRUG | October 2021 | April 2025 | Allow | 42 | 1 | 0 | No | No |
| 17448549 | DOSING REGIME AND FORMULATIONS FOR TYPE B ADENOVIRUSES | September 2021 | February 2025 | Allow | 41 | 1 | 0 | Yes | No |
| 17440372 | ADOPTIVE CELL THERAPY | September 2021 | December 2024 | Abandon | 39 | 1 | 0 | No | No |
| 17463262 | CODON OPTIMIZED REP1 GENES AND USES THEREOF | August 2021 | February 2022 | Allow | 5 | 0 | 0 | No | No |
| 17433222 | TUMOR-NAVIGATING, SELF-ERADICATING, TRAIL-ARMED SALMONELLA FOR PRECISION CANCER THERAPY | August 2021 | August 2022 | Allow | 12 | 1 | 0 | No | No |
| 17400974 | PRIMARY CELL GENE EDITING | August 2021 | May 2025 | Abandon | 45 | 1 | 0 | No | No |
| 17387347 | Chimeric T Cell Receptors, Nucleic Acids, And Methods Of Making And Using The Same | July 2021 | November 2024 | Allow | 40 | 3 | 0 | No | No |
| 17339597 | TRANSPOSITION OF NUCLEIC ACID CONSTRUCTS INTO EUKARYOTIC GENOMES WITH A TRANSPOSASE FROM AMYELOIS | June 2021 | March 2022 | Allow | 9 | 1 | 1 | No | No |
| 17327625 | THERAPEUTIC USES OF GENOME EDITING WITH CRISPR/Cas SYSTEMS | May 2021 | April 2024 | Abandon | 35 | 4 | 0 | No | Yes |
| 17241546 | POLYEPITOPE CONSTRUCTS FOR USE IN IMMUNOTHERAPY | April 2021 | September 2024 | Abandon | 40 | 2 | 0 | No | No |
| 17240845 | Optimized Liver-Specific Expression Systems for FVIII and FIX | April 2021 | October 2024 | Abandon | 41 | 1 | 0 | No | No |
| 17287434 | SYNP151 (PROC29), A PROMOTER FOR THE SPECIFIC EXPRESSION OF GENES IN RETINAL GANGLION CELLS | April 2021 | December 2024 | Abandon | 44 | 1 | 0 | No | No |
| 17194009 | AAV VECTORS FOR RETINAL AND CNS GENE THERAPY | March 2021 | October 2024 | Allow | 44 | 1 | 0 | No | No |
| 17255091 | NATURAL KILLER CELLS | December 2020 | May 2025 | Allow | 52 | 1 | 1 | Yes | No |
| 17055056 | COMPOSITIOINS FOR INDUCING AN IMMUNE RESPONSE | November 2020 | November 2024 | Allow | 48 | 1 | 1 | No | No |
| 17090110 | Dry Transfection Compositions and Methods for Making and Using the Same | November 2020 | May 2025 | Allow | 55 | 5 | 0 | No | No |
| 17079006 | BCMA CHIMERIC ANTIGEN RECEPTORS | October 2020 | October 2023 | Allow | 35 | 1 | 0 | No | No |
| 17079072 | BCMA CHIMERIC ANTIGEN RECEPTORS | October 2020 | April 2021 | Allow | 6 | 1 | 0 | No | No |
| 17071707 | THERAPEUTIC METHODS AND COMPOSITIONS FOR SOLID DELIVERY | October 2020 | January 2024 | Abandon | 39 | 1 | 0 | No | No |
| 17067302 | LIPOSOME COMPOSITION | October 2020 | March 2021 | Allow | 6 | 1 | 0 | No | No |
| 16980345 | INDUCIBLE T CELL RECEPTORS AND USES THEREOF | September 2020 | February 2025 | Allow | 53 | 1 | 0 | Yes | No |
| 17013195 | SELECTION METHODS FOR GENETICALLY-MODIFIED T CELLS | September 2020 | March 2024 | Abandon | 42 | 1 | 0 | No | No |
| 17010587 | GENETICALLY MODIFIED NON-HUMAN ANIMALS WITH HUMANIZED IMMUNOGLOBULIN LOCUS | September 2020 | March 2024 | Allow | 43 | 6 | 1 | Yes | No |
| 16977015 | STEM CELL-DERIVED EXOSOMES FOR THE TREATMENT OF CORNEAL SCARRING | August 2020 | November 2024 | Allow | 50 | 1 | 1 | No | No |
| 16976168 | LIPOSOMAL SPHERICAL NUCLEIC ACID (SNA) CONSTRUCTS FOR SURVIVAL OF MOTOR NEURON (SMA) INHIBITORS | August 2020 | July 2024 | Abandon | 47 | 1 | 0 | No | No |
| 16975545 | NOVEL ADENO-ASSOCIATED VIRUS (AAV) VECTORS, AAV VECTORS HAVING REDUCED CAPSID DEAMIDATION AND USES THEREFOR | August 2020 | May 2025 | Allow | 56 | 2 | 0 | Yes | Yes |
| 17000105 | Humanized M-CSF Mice | August 2020 | June 2024 | Allow | 46 | 2 | 0 | Yes | No |
| 16994388 | CANCER STEM CELL POPULATION AND METHOD FOR PRODUCTION THEREOF | August 2020 | December 2023 | Allow | 40 | 1 | 0 | No | No |
| 16992196 | THERAPEUTIC IMMUNE CELLS WITH IMPROVED FUNCTION AND METHODS FOR MAKING THE SAME | August 2020 | October 2023 | Abandon | 38 | 1 | 0 | No | No |
| 16968664 | CRISPR/CAS9 VECTOR COMBINATION AND APPLICATION THEREOF IN GENE KNOCKOUT | August 2020 | July 2021 | Allow | 11 | 1 | 0 | Yes | No |
| 16986946 | METHODS AND COMPOSITIONS FOR TREATING METASTATIC BREAST CANCER AND OTHER CANCERS IN THE BRAIN | August 2020 | August 2023 | Allow | 37 | 1 | 0 | Yes | No |
| 16966287 | METHODS FOR PREVENTING AND TREATING TYPE II DIABETES | July 2020 | September 2024 | Allow | 50 | 2 | 1 | Yes | No |
| 16933154 | METHODS FOR TREATING MUSCULAR DYSTROPHY | July 2020 | July 2023 | Abandon | 36 | 1 | 0 | No | No |
| 16963034 | GENOME ENGINEERING WITH CRISPR-CAS SYSTEMS IN EUKARYOTES | July 2020 | March 2025 | Allow | 56 | 2 | 1 | Yes | No |
| 16916482 | VESICULAR STOMATITIS VIRUSES | June 2020 | December 2022 | Allow | 29 | 1 | 0 | No | No |
| 16903257 | MOTOR NEURON-SPECIFIC EXPRESSION VECTORS | June 2020 | January 2023 | Allow | 31 | 1 | 0 | No | No |
| 16896021 | CAS9 NUCLEIC ACID MOLECULES AND THEIR USE | June 2020 | December 2022 | Allow | 30 | 1 | 0 | No | No |
| 16893166 | PRIMARY CELL GENE EDITING | June 2020 | August 2021 | Abandon | 15 | 2 | 0 | Yes | No |
| 16891978 | METHODS AND COMPOSITIONS FOR THE TARGETED MODIFICATION OF A GENOME | June 2020 | July 2023 | Allow | 37 | 1 | 0 | No | No |
| 16885874 | TUMOR INFILTRATING LYMPHOCYTES AND METHODS OF THERAPY | May 2020 | June 2021 | Allow | 13 | 0 | 1 | Yes | No |
| 15733107 | Therapy For Myotonic Dystrophy Type 1 Via Genome Editing of the DMPK Gene | May 2020 | March 2025 | Abandon | 58 | 4 | 1 | No | No |
| 16842709 | TRANSPOSITION OF NUCLEIC ACID CONSTRUCTS INTO EUKARYOTIC GENOMES WITH A TRANSPOSASE FROM AMYELOIS | April 2020 | April 2021 | Allow | 12 | 1 | 1 | No | No |
| 16837610 | BCMA CHIMERIC ANTIGEN RECEPTORS | April 2020 | December 2022 | Allow | 32 | 1 | 0 | No | No |
| 16650987 | THREAD COLLECTING DEVICE | March 2020 | June 2023 | Allow | 38 | 1 | 0 | No | No |
| 16820101 | METHOD FOR IN VITRO FERTILIZATION IN A BIOREACTOR | March 2020 | August 2024 | Allow | 53 | 3 | 0 | No | No |
| 16645707 | RNA REPLICON FOR REPROGRAMMING SOMATIC CELLS | March 2020 | December 2024 | Allow | 58 | 3 | 0 | Yes | No |
| 16807943 | GENETIC MARKERS FOR ENGRAFTMENT OF HUMAN CARDIAC VENTRICULAR PROGENITOR CELLS | March 2020 | March 2023 | Allow | 36 | 1 | 0 | No | No |
| 16799818 | Renovation and Repopulation of Decellularized Tissues and Cadaveric Organs by Stem Cells | February 2020 | July 2023 | Abandon | 41 | 1 | 0 | No | No |
| 16784230 | ISOLATED LIVER CANCER STEM CELL AND METHOD FOR DRUG SCREENING THEREOF | February 2020 | June 2023 | Allow | 40 | 2 | 0 | No | No |
| 16635857 | Treatment of Local Skin Hypotrophy Conditions | January 2020 | June 2024 | Abandon | 53 | 1 | 0 | No | No |
| 16742670 | TAURINE SUPPLEMENTED CELL CULTURE MEDIUM AND METHODS OF USE | January 2020 | November 2020 | Allow | 11 | 1 | 0 | No | No |
| 16724508 | COMPOSITIONS AND METHODS FOR THE STUDY AND TREATMENT OF ACUTE KIDNEY INJURY | December 2019 | November 2023 | Abandon | 46 | 2 | 0 | No | No |
| 16722071 | COMPOSITIONS AND METHODS FOR PEST CONTROL MANAGEMENT | December 2019 | October 2022 | Allow | 33 | 1 | 0 | No | No |
| 16714127 | TREATMENT OF CANCER USING TLR9 AGONIST WITH CHECKPOINT INHIBITORS | December 2019 | November 2023 | Abandon | 47 | 2 | 0 | No | No |
| 16696456 | Methods, Devices and Systems for Enhanced Transduction Efficiency | November 2019 | March 2024 | Allow | 52 | 2 | 0 | Yes | No |
| 16613616 | REPROGRAMMING METABOLISM BY INHIBITING VHL FOR TREATMENT OF NEURODEGENERATION | November 2019 | November 2023 | Abandon | 48 | 2 | 0 | No | No |
| 16662987 | ADENO-ASSOCIATED VIRUS VIRIONS WITH VARIANT CAPSID AND METHODS OF USE THEREOF | October 2019 | February 2023 | Abandon | 40 | 1 | 0 | No | No |
| 16656497 | PIF-TRANSFECTED CELLS AND METHODS OF USE | October 2019 | October 2023 | Abandon | 48 | 1 | 0 | No | No |
| 16500706 | ADENO-ASSOCIATED VIRUS CAPSID VARIANTS AND METHODS OF USE THEREOF | October 2019 | January 2023 | Allow | 39 | 1 | 0 | Yes | No |
| 16584616 | RECOMBINANT AAV VARIANTS AND USES THEREOF | September 2019 | June 2022 | Allow | 33 | 0 | 0 | No | No |
| 16578893 | METHODS, SYSTEMS, AND COMPOSITIONS FOR NEURONAL DIFFERENTIATION OF MULTIPOTENT STROMAL CELLS | September 2019 | December 2022 | Abandon | 39 | 1 | 0 | No | No |
| 16577857 | NEUROPROTECTIVE MOLECULES AND METHODS OF TREATING NEUROLOGICAL DISORDERS AND INDUCING STRESS GRANULES | September 2019 | June 2024 | Abandon | 57 | 2 | 0 | No | Yes |
| 16572248 | Using Truncated Guide RNAs (tru-gRNAs) to Increase Specificity for RNA-Guided Genome Editing | September 2019 | December 2022 | Allow | 39 | 1 | 0 | Yes | No |
| 16489018 | SHP INHIBITOR COMPOSITIONS AND USES FOR CHIMERIC ANTIGEN RECEPTOR THERAPY | August 2019 | January 2025 | Abandon | 60 | 2 | 1 | No | Yes |
| 16541083 | METHODS FOR TRANSDUCTION AND CELL PROCESSING | August 2019 | June 2023 | Allow | 46 | 1 | 1 | No | No |
| 16485094 | METHODS AND COMPOSITIONS FOR GENE TRANSFER ACROSS THE VASCULATURE | August 2019 | October 2023 | Allow | 50 | 2 | 0 | No | No |
| 16513999 | MARKERS FOR BREAST CANCER | July 2019 | December 2022 | Abandon | 41 | 1 | 0 | No | No |
| 16504853 | BCMA CHIMERIC ANTIGEN RECEPTORS | July 2019 | January 2020 | Allow | 6 | 1 | 0 | No | No |
| 16504859 | BCMA CHIMERIC ANTIGEN RECEPTORS | July 2019 | January 2020 | Allow | 6 | 1 | 0 | No | No |
| 16502972 | BCMA CHIMERIC ANTIGEN RECEPTORS | July 2019 | December 2019 | Allow | 6 | 1 | 0 | No | No |
| 16502966 | BCMA CHIMERIC ANTIGEN RECEPTORS | July 2019 | December 2019 | Allow | 6 | 1 | 0 | No | No |
| 16447812 | NUCLEIC ACID ENCODING GENETICALLY ENGINEERED GROWTH FACTOR VARIANTS | June 2019 | July 2024 | Abandon | 60 | 4 | 0 | Yes | No |
| 16443841 | Population-Hastened Assembly Genetic Engineering | June 2019 | January 2025 | Abandon | 60 | 2 | 1 | No | Yes |
| 16434714 | TUMOR-TARGETING SYNTHETIC ADENOVIRUSES AND USES THEREOF | June 2019 | June 2023 | Allow | 49 | 2 | 0 | No | No |
| 16465109 | ENGINEERED B CELLS AND RELATED COMPOSITIONS AND METHODS | May 2019 | June 2023 | Allow | 48 | 1 | 1 | Yes | No |
| 16411848 | Novel Liver Targeting Adeno-Associated Viral Vectors | May 2019 | June 2023 | Allow | 49 | 2 | 0 | Yes | No |
| 16395865 | Tolerogenic DNA Vaccine | April 2019 | July 2021 | Allow | 26 | 3 | 1 | No | No |
| 16384571 | GENE VECTOR | April 2019 | March 2022 | Allow | 35 | 0 | 0 | No | No |
| 16340758 | USE OF TONICIFYING AGENTS TO ENHANCE RECOMBINANT ADENO-ASSOCIATED VIRUS YIELD | April 2019 | June 2023 | Allow | 50 | 2 | 0 | No | No |
| 16366826 | NON-HUMAN ANIMALS HAVING A DISRUPTION IN A C9ORF72 LOCUS | March 2019 | August 2022 | Allow | 41 | 1 | 0 | Yes | No |
| 16296925 | NOVEL PLGA-MODIFIED POLYETHYLENIMINE SELF-ASSEMBLY NANOTECHNOLOGY FOR NUCLEIC ACID AND DRUG DELIVERY | March 2019 | August 2022 | Allow | 42 | 1 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner ARON, KIMBERLY A.
With a 33.3% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 6.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner ARON, KIMBERLY A works in Art Unit 1633 and has examined 410 patent applications in our dataset. With an allowance rate of 52.7%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 39 months.
Examiner ARON, KIMBERLY A's allowance rate of 52.7% places them in the 9% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by ARON, KIMBERLY A receive 2.45 office actions before reaching final disposition. This places the examiner in the 84% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by ARON, KIMBERLY A is 39 months. This places the examiner in the 9% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +35.1% benefit to allowance rate for applications examined by ARON, KIMBERLY A. This interview benefit is in the 86% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 19.6% of applications are subsequently allowed. This success rate is in the 13% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 21.2% of cases where such amendments are filed. This entry rate is in the 19% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.
When applicants request a pre-appeal conference (PAC) with this examiner, 80.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 60% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 77.8% of appeals filed. This is in the 65% percentile among all examiners. Of these withdrawals, 90.5% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 73.1% are granted (fully or in part). This grant rate is in the 89% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.5% of allowed cases (in the 59% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.9% of allowed cases (in the 55% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.